Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062230 | 0.95 | OPRM1 (0.56) | OPRM1CHRM2CHRM3SIGMAR1ACHE | |
| SCHEMBL1207106 | 0.93 | OPRM1 (0.54) | OPRM1CHRM2CHRM3SIGMAR1ACHE | |
| SCHEMBL1307812 | 0.92 | OPRM1 (0.55) | OPRM1CHRM2CHRM3SIGMAR1ACHE | |
| SCHEMBL5672524 | 0.88 | SIGMAR1 (0.50) | OPRM1SIGMAR1ACHEHTR2AKCNH2 | |
| SCHEMBL4125301 | 0.86 | ACHE (0.57) | SIGMAR1ACHE | |
| SCHEMBL1921490 | 0.86 | SIGMAR1 (0.56) | OPRM1SIGMAR1ACHE | |
| SCHEMBL10893210 | 0.86 | CHRM2 (0.56) | OPRM1CHRM2CHRM3SIGMAR1ACHE | |
| SCHEMBL20544081 | 0.84 | KDM4E (0.55) | OPRM1CHRM2CHRM3ACHE | |
| SCHEMBL20544083 | 0.84 | KDM4E (0.55) | OPRM1CHRM2CHRM3ACHE | |
| SCHEMBL1921304 | 0.83 | SIGMAR1 (0.53) | OPRM1SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-09-13 | — | — | US | disclosed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| EP-1078928-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-05-12 | — | — | EP | disclosed |
| EP-1078928-A1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0111397-B1 | ISOINDOLE DERIVATIVES, PREPARATION, AND USES | Bristol-Myers Company (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4600758-A | 5-SULFAMOYL-3-OXOISOINDOLES WITH ARLYPIPERIDINYL MOIETIES, DIURETICS, HYPOTENSIVES | MEAD JOHNSON & COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-4495194-A | HYPOTENSIVE AGENTS; DIURETICS | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0111397-A1 | Isoindole derivatives, preparation, and uses | Bristol-Myers Company (US) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | OPRM1 3895/4885CHRM2 3729/4885CHRM3 3215/4885 |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | OPRM1 4385/4885CHRM2 4804/4885CHRM3 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.